Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04387084
Title Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of Southern California
Indications

Advanced Solid Tumor

Therapies

Durvalumab

Pembrolizumab

Avelumab

Cemiplimab

Atezolizumab

Nivolumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.